Scarica l'app Stockscreener
4.08
2.39%
-0.10
Dopo l'orario di chiusura:
4.10
0.02
+0.49%
Precedente Chiudi:
$4.18
Aprire:
$4.2
Volume 24 ore:
2.38M
Relative Volume:
0.37
Capitalizzazione di mercato:
$888.23M
Reddito:
$76.20M
Utile/perdita netta:
$-17.37M
Rapporto P/E:
448.35
EPS:
0.0091
Flusso di cassa netto:
$-75.81M
1 W Prestazione:
-0.97%
1M Prestazione:
-10.53%
6M Prestazione:
-3.09%
1 anno Prestazione:
+324.47%
Intervallo 1D:
$4.04
$4.255
Intervallo di 1 settimana:
$3.99
$4.38
Portata 52W:
$0.9041
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.08 | 910.00M | 76.20M | -17.37M | -75.81M | 0.0091 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2026-01-20 | Iniziato | Guggenheim | Buy |
| 2025-09-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
| 2021-11-15 | Iniziato | BTIG Research | Buy |
| 2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Iniziato | JP Morgan | Overweight |
| 2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-06-01 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-11-26 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-15 | Iniziato | Goldman | Neutral |
| 2018-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2018-06-01 | Iniziato | SunTrust | Buy |
| 2018-01-05 | Iniziato | Citigroup | Buy |
| 2017-09-08 | Iniziato | Wedbush | Outperform |
| 2017-03-27 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
MSN Money - MSN
CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Certain Restricted Stock Units of CytomX Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2026. - marketscreener.com
170,186,365 Common Stock of CytomX Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2026. - marketscreener.com
CytomX (NASDAQ: CTMX) proxy adds share capacity and expands equity plans - Stock Titan
CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 - Yahoo Finance UK
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - MSN
CytomX stock rises 31% in a month: Here's what you should know - MSN
Cantor Fitzgerald Initiates Coverage of CytomX Therapeutics (CTMX) with Overweight Recommendation - MSN
CytomX Therapeutics launches $250M public offering - MSN
Wall Street Zen Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Strong Sell - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50-Day Moving AverageHere's What Happened - MarketBeat
CytomX Therapeutics prices $250M public offering at $5.30 per share - MSN
CTMX Stock Price, Quote & Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
CTMX (CytomX Therapeutics Inc.) shares climb over 7 percent despite wider than expected Q4 2025 per share losses.Margin of Safety - Cổng thông tin điện tử tỉnh Tây Ninh
Small Cap or Megacap: Which Healthcare Stock Is Right for You? - The Motley Fool
CTMX Forecast, Price Target & Analyst Ratings | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
Analysts bullish on CytomX Therapeutics (CTMX) as CTMX prices $250 million offering - MSN
CytomX (NASDAQ: CTMX) seeks shareholder OK to double authorized shares to 600M - Stock Titan
CytomX Therapeutics (CTMX) gains analyst confidence on trial progress - MSN
HC Wainwright & Co. Maintains CytomX Therapeutics (CTMX) Buy Recommendation - MSN
CytomX Therapeutics (CTMX) making progress on key metastatic colorectal cancer treatment - MSN
CytomX Therapeutics Inc Share PriceCTMX, RNS News, Articles, Quotes, & Charts (NASDAQ:CTMX) - Proactive financial news
CTMX SEC FilingsCytomx Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Why CTMX Stock Is Soaring 54% Pre-Market Today? - MSN
Point72 (CTMX) reports 10,864,581 shares, a 5.0% holding in CytomX - Stock Titan
Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX) - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 6.3%Time to Buy? - MarketBeat
CytomX Therapeutics, Inc. (CTMX) Stock Analysis: Exploring a 199.71% Potential Upside in the Biotech Innovator - DirectorsTalk Interviews
CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress - Insider Monkey
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):